Shots:  Alvotech entered into a long-term agreement with Teva Pharmaceuticals to expand access to newly US FDA-approved higher concentration Adalimumab-ryvk, an interchangeable biosimilar to Humaira in US market  The partnership agreement aims to broaden access and further availability assurance of biologics for patients at affordable prices in the US and globally  Following commercialization collaboration between…